SAN FRANCISCO, Oct 28, 2002 (BUSINESS WIRE) -- Exelixis, Inc. (Nasdaq: EXEL) today announced the establishment of a broad alliance with GlaxoSmithKline to discover and develop novel therapeutics. Exelixis will host a conference call at 5:00 pm ET to discuss this new alliance. The call will be led by George A. Scangos, Ph.D., president and chief executive officer, with other senior management participating.

The call will be webcast on the investor relations section of Exelixis' website at www.exelixis.com/ir (click on the Corporate Collaboration icon) and at www.ccbn.com and will be archived until November 11, 2002.

Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery company focused on product development through its expertise in comparative genomics and model system genetics. These technologies provide a rapid, efficient and cost effective way to move from DNA sequence data to knowledge about the function of genes and the proteins they encode. The company's technology is broadly applicable to all life sciences industries including pharmaceutical, diagnostic, agricultural biotechnology and animal health. Exelixis has partnerships with Bayer CropScience, Bristol-Myers Squibb, Cytokinetics, Dow Agrosciences, Elan Pharmaceuticals, Merck, Protein Design Labs, Schering-Plough Research Institute and Scios and is building its internal development program in the area of oncology. For more information, please visit the company's web site at www.exelixis.com.Exelixis and the Exelixis logo are registered U.S. trademarks.

CONTACT:          Exelixis, Inc.
                  Jane M. Green, 650/837-7579
                  jmgreen@exelixis.com

URL:              http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire.  All rights reserved.